Breaking News

UPS Expands Healthcare Network

October 26, 2012

Adds three new Asia-Pac facilities

UPS has expanded its global healthcare distribution facility network in the Asia Pacific region with the opening of three new facilities in Sydney, Australia and Hangzhou and Shanghai, China. The new facilities bring the total number of UPS healthcare facilities around the world to 36 and include 35,000 square meters of healthcare-compliant distribution space designed for pharma, biotech and medical device companies.
The Hangzhou facility consists of 22,000 square meters of validated healthcare distribution space to support pharmaceutical companies that are setting up manufacturing operations in China. The 7,575-square-meter facility in Shanghai is designed to meet the needs of the medical device market and is in close proximity to the Waigaoqiao Free Trade Zone and the UPS International Air Hub in Shanghai. The 5,388-square-meter facility in Sydney offers dedicated healthcare distribution space for multi-national and regional companies looking to set up distribution in Sydney to serve regional markets.

“Asia is our fastest-growing market for healthcare and we are seeing increased activity in the region, especially in China, where a growing demand for acute and chronic care has driven the need for reliable, flexible and compliant supply chains to serve a highly dynamic market,” said Bill Hook, vice president, global strategy, UPS Healthcare Logistics. “Healthcare is a major focus area for UPS, and we are committed to continuing investments in Asia and other parts of the world timed with — and often ahead of — market demand to support our clients’ growth strategies in key regions.”

Related Packaging:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks